The investigational agent was designed to reduce the gastrointestinal side effects observed with galantamine. The Food and Drug Administration (FDA) has accepted for review the New Drug Application ...

Please provide your email address to receive an email when new articles are posted on . A Vancouver-based biopharmaceutical company has secured a notice of allowance, presaging a U.S. patent for a ...